Nektar's Rezpegaldesleukin Hits Key Endpoints in Atopic Dermatitis Trial
Event summary
- Nektar Therapeutics published Phase 2b REZOLVE-AD trial results in The Lancet, showing rezpegaldesleukin met all primary and key secondary endpoints in moderate-to-severe atopic dermatitis.
- The 16-week induction study across 107 sites in 10 countries involved 393 patients, demonstrating dose-dependent efficacy improvements over placebo.
- Rezpegaldesleukin showed rapid onset of efficacy, consistent responses across disease severity, and a favorable safety profile with no increased risk of infections.
- Phase 3 ZENITH AD program is underway, with trials initiated in July 2026 and planned for September 2026.
The big picture
Nektar's results mark the first large, placebo-controlled trial demonstrating that selectively expanding regulatory T cells can translate into clinically meaningful improvements in atopic dermatitis. This novel mechanism, working upstream of current therapies, could alter the treatment paradigm for moderate-to-severe AD patients. The Phase 3 program's success will be critical for Nektar's strategic positioning in the competitive autoimmune and inflammatory disease market.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 ZENITH AD program can secure regulatory approval given the positive Phase 2b data.
- Market Differentiation
- How rezpegaldesleukin's unique T-reg mechanism will position it against existing cytokine-inhibiting therapies.
- Pipeline Expansion
- The pace at which Nektar can advance rezpegaldesleukin into other indications like alopecia areata and Type 1 diabetes.
Related topics